'BioConversations'
Agnostic of the gender, leadership qualities come from passion, vision, and foresight for ushering meaningful changes for a better tomorrow. For a leader to lead, it is the leadership quality that takes precedence over the binary of gender. Celebrating Women’s Day and Making Each One Count In a display of great camaraderie and participation, Biocon … Continue reading Biocon Biologics Commemorates International Women’s Day 2024 with a Focus on Diversity & Inclusion
Women have long defied boundaries and shattered gender stereotypes, embarking on journeys to seize control of their lives by navigating challenges and taking control of their destinies. Cherishing a legacy of 45 years, Biocon group traces its roots to a brainchild of young and confident Ms Kiran Mazumdar-Shaw whose indomitable spirit led to the setting … Continue reading Agents of Change, Women bring Value to Science
By Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics In the Interim Union Budget 2024-25, Finance Minister Nirmala Sitharaman has provided a comprehensive roadmap for sustained economic growth that will enable India to achieve a developed economy status by 2047. The global economy went through a volatile period between 2020 and 2023. However, India’s GDP … Continue reading A Vision of ‘Viksit Bharat’, Driven by Inclusion & Innovation
Know Bengaluru Tech Summit Bengaluru Tech Summit (BTS) is a platform for knowledge sharing, discussions, best industry practices, transformative insights and thought leadership to the stakeholders and participants, covering various gamut of technologies, innovation and entrepreneurship. The three-day event was inaugurated by Karnataka Chief Minister Siddaramaiah on November 29, 2023, at the Bangalore Palace. … Continue reading Govt Support in Fundamental Research key to make India a truly knowledge based Economy
What Drives Corporate Reputation of a Pharma Brand? A new film has released, and you can’t make up your mind whether it’s worth your time and money. What do you do? Well, reading some reviews might help, or maybe a recommendation from a friend. In either instance, you decision would be based on the reputation … Continue reading What Drives Corporate Reputation of a Pharma Brand?
Biocon Biologics marked a key milestone in the post-acquisition integration of the biosimilars business of its long-term partner Viatris with the successful transitioning of the business in North America (United States and Canada) on September 1, 2023. It marks Biocon Biologics’ first direct commercial presence in Advanced Markets and represents the largest share of its … Continue reading Biocon Biologics Marks Another Key Milestone with Successful Transition of the North America Business Ahead of Plan
Biocon Biologics’ (BBL) revenues for Q1 FY24 saw an over 100% year-on-year growth, driven by the consolidation of the biosimilars business acquired from Viatris, as well as higher sales of commercialized products that is reflected in their market share gains in U.S. & Europe. The robust performance this quarter has given Biocon Biologics the impetus … Continue reading Consolidation of acquired business fuels Biocon Biologics’ growth trajectory
Biocon Biologics Limited (BBL) got off to a promising start to FY24 with an over two-fold increase in first-quarter revenues, truly reflecting the “Power of One” derived from the Company's transformative acquisition of the global biosimilars of its long-term partner Viatris. Driven by market share gains for its commercialized biosimilars in key markets and the … Continue reading Delivering on ‘Power of One’; Biocon Biologics starts FY24 on a Strong Footing with 2-fold Revenue Jump in Q1
Biocon Biologics Ltd (BBL) has ended financial year 2023 (FY23) on a high. The year marks an inflection point in its value creation journey as the acquisition of partner Viatris’ biosimilars business has catapulted the company into the global big league. BBL more than doubled its revenue on a YoY basis to Rs 2,102 crore … Continue reading Biocon Biologics Ends FY23 on a $1 billion Annual Revenue Trajectory
The World Health Organization recently declared that Covid-19 is no longer a global health emergency. While the pandemic threat has waned, there continues to be huge unmet need for affordable essential medicines to treat chronic diseases that kill 41 million people each year. Over the last two decades, Biocon has been at the forefront of … Continue reading Biocon Reports a Robust Business Performance in FY23
Only company from the global biotech industry to be recognized as ‘industry mover’ Biocon (including Biocon Biologics) is proud to be recognized as the “Industry Mover” in the S&P Global Sustainability Yearbook 2023. Biocon is the only company to be named as “Industry Mover” this year from the Biotechnology industry. Biocon is also the only Biotechnology company from … Continue reading Biocon Recognized Among World’s Most Sustainable Companies in S&P Global 2023 Sustainability Yearbook
The world is just emerging from the economic impact of the COVID-19 pandemic. The people who suffered the economic fallout of the pandemic as their incomes shrunk, urgently need of access to cheaper drugs. This has been the case not only in the emerging markets, but also in the developed countries. Generics and biosimilars which … Continue reading Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
The global economy is in its steepest slowdown since 1970. The IMF has forecast that global economic growth will slow to 3.2% in 2022 and 2.9% in 2023 from 6.1% in 2021. While high inflation continues to make headlines across the globe, spiralling healthcare costs need to be addressed. Biosimilars, which provide affordable access to … Continue reading Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
Tricolor Distributed Among Children of govt schools, to Communities and Biocon Group’s staff amidst the singing of the National Anthem and National Song The Biocon Group participated in the Diamond Jubilee (75 years) celebrations of India’s Freedom over three days. The Har Ghar Tiranga campaign, initiated by the Government of India, had a good response; the Biocon Group of companies came together to distribute 30,000 flags among schoolchildren, their parents, general public and Biocon’s employees.
Biocon's Chairperson Kiran Mazumdar-Shaw in a QnA with FE’s Srinath Srinivasan, talks about the bold moves Biocon Biologics is making since 2021, including the recent acquisition of Viatris’ global biosimilars business, which will provide it a direct entry into the US & Europe with the acquired commercial engine in developed and key emerging markets. This … Continue reading Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
India's premier biopharmaceutical company Biocon is working on a pipeline of 20 biosimilar drugs or similar but not identical copy of biologic medicines, to tap the upcoming huge opportunity. Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products. It has biosimilars in oncology like … Continue reading Biocon developing 20 biosimilar products for global markets
By Dr. Viraj Suvarna Is there a real issue about access to diabetes care? Sir Francis Peabody, renowned physician, says, that the secret in the caring of the patient is in caring for the patient. In other words, despite a plethora of options, Indian patients with diabetes still do not have access to comprehensive diabetes … Continue reading Access to diabetes care; if not now, when?
A Blog by Biocon 